Related Experiment Video
Updated: Jan 28, 2026

Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
Canagliflozin review - safety and efficacy profile in patients with T2DM
Haroon Jakher1, Tara I Chang2, Marilyn Tan3
1Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA, hjakher@stanford.edu.
Abstract:
Canagliflozin is a sodium glucose-cotransporter (SGLT) receptor inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). This article reviews the mechanism of action of SGLT-2 receptor inhibitors and the efficacy of canagliflozin as an antidiabetic agent, its cardiovascular and renal benefits, and safety profile. During the development of canagliflozin, Phase II trials showed an improvement in cardiac and renal biomarkers such as blood pressure, body weight, and albuminuria. The large CANVAS program showed that canagliflozin reduced the composite cardiovascular outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The CANVAS program also showed a possible benefit of canagliflozin on a renal composite of sustained 40% reduction in estimated glomerular filtration rate, the need for renal replacement therapy, or death from renal causes. The safety profile of canagliflozin has been well characterized, and known side effects such as mycotic genital infections were confirmed in CANVAS. However, an increased risk of amputations was observed in CANVAS that requires further study. Overall, canagliflozin is an effective antidiabetic medication with cardiovascular and likely renal benefits, and with a generally well-tolerated safety profile. Results from the CREDENCE trial will further evaluate the safety and potential renal benefits of canagliflozin in patients with established diabetic nephropathy.
Insights
Canagliflozin, a sodium glucose-cotransporter 2 inhibitor, effectively treats type 2 diabetes. It offers significant cardiovascular and potential renal benefits, though amputation risk needs monitoring.
Area of Science:
- Pharmacology
- Cardiology
- Nephrology
Background:
- Type 2 diabetes mellitus (T2DM) management requires agents with broad efficacy.
- Sodium glucose-cotransporter 2 (SGLT2) inhibitors represent a novel therapeutic class.
- Canagliflozin targets SGLT2 to lower blood glucose.
Purpose of the Study:
- To review the mechanism of action of SGLT2 inhibitors.
- To evaluate canagliflozin's efficacy, cardiovascular and renal benefits, and safety.
- To discuss findings from the CANVAS program and ongoing trials like CREDENCE.
Main Methods:
- Review of Phase II trials and the large CANVAS program data.
- Analysis of cardiovascular and renal composite outcomes.
- Assessment of canagliflozin's safety profile, including adverse events.
Main Results:
- Canagliflozin improved cardiac and renal biomarkers in Phase II trials.
- The CANVAS program demonstrated reduced cardiovascular events with canagliflozin.
- Potential renal benefits and confirmed side effects like genital infections were noted; amputation risk requires further investigation.
Conclusions:
- Canagliflozin is an effective antidiabetic agent with demonstrated cardiovascular benefits.
- Evidence suggests likely renal protective effects, warranting further study in specific populations.
- The safety profile is generally favorable, with specific adverse events identified for clinical awareness.
More Related Videos
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Survey Safety
Self-Efficacy
Household Wiring And Electrical Safety
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...

